Iranian Heart Journal

Iranian Heart Journal

Comparison of the One-Year Outcome Between Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease

Document Type : Original Article

Authors
Mohammed Rouzbahani 1
Zahra Shirazinezhad 1
Yahya Salimi 2
Parisa Janjani 1
Nahid Salehi 1
Alireza Rai 1
Javad Azimivaghar 1
Arsalan Naderipour 3
Somayeh Shirazinezhad 4
Etrat Javadi rad 5
Reza Heidari moghadam 1
1 Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
2 Social Development and Health Promotion Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
3 Department of Emergency Medicine, School of Paramedics, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
4 Department of Radiology, Isfahan University of Medical Sciences, Isfahan, IR Iran.
5 Clinical Research Development Center of Imam Khomeini Hospital, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
Abstract
Background: Our study aimed to compare the 1-year therapeutic outcome between coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD).
 
Methods: This retrospective cohort study was conducted on 150 patients with multivessel CAD who underwent CABG or PCI in Imam Ali Cardiovascular Center, Kermanshah, Iran, between March 2017 and March 2019. Data were collected using a checklist developed based on the study objectives. Differences between subgroups were assessed by using the independent t test and the χ2 test (or the Fisher exact test). A multivariate binary logistic regression model was used to determine factors associated with referral to CABG or PCI.
 
Results: The mean age was 63.48 (SD=9.73) years in the PCI group and 60.54 (SD=10.85) years in the CABG group (P=0.741). The CABG group was more likely to have left main disease (16.6% vs 0%; P<0.001). The PCI group was more likely to take an antiplatelet (viz, clopidogrel) and nitrates, whereas the CABG group was more likely to take antihypertensives (angiotensin receptor blockers) and anticoagulants (viz, rivaroxaban and warfarin) (P<0.05). The CABG had significantly higher rates of major bleeding (P=0.003) and arrhythmia (P=0.045) than the PCI group. There was a significant difference in the mortality between the 2 treatment groups (9.3% of the CABG group vs 1.3% of the PCI group; P=0.029). Left main disease was associated with an increased odds of referral to CABG (OR=0.02; P=0.015).
 
Conclusions: PCI was associated with a lower adverse clinical outcome than CABG in patients with multivessel CAD. (Iranian Heart Journal 2022; 23(1): 25-33)
Keywords
Coronary artery bypass grafting
Coronary artery disease
Iran
Outcome
Angioplasty
  1. Shyu K-G, Wu C-J, Mar G-Y, Hou CJ-Y, Li A-H, Wen M-S, et al. Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndromed observations from the Taiwan ACS full spectrum registry. Acta Cardiol Sin 2011; 27: e44.
  2. Feeman Jr W. Risk factors versus inflammation in atherothrombotic disease. Circulation 2002; 106: e31.
  3. Shemirani H, Separham K. The relative impact of smoking or Hypertension on severity of premature coronary artery disease. 2007.
  4. Doughty M, Mehta R, Bruckman D, Das S, Karavite D, Tsai T, et al. Acute myocardial infarction in the young—The University of Michigan experience. American heart journal 2002; 143: 56-62.
  5. Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC: Cardiovascular Interventions 2010; 3: 1059-67.
  6. Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. Journal of the American College of Cardiology 2001; 37: 51-8.
  7. Frye RL, Alderman EL, Andrews K, Bost J, Bourassa M, Chaitman BR, et al. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) investigators. New England Journal of Medicine 1996; 335: 217-25.
  8. Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. The Lancet 1998; 352: 1419-25.
  9. Investigators BARI. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. New England Journal of Medicine 1996; 335: 217-25.
  10. Participants CT. First-year results of CABRI (coronary angioplasty versus bypass revascularisation investigation). The Lancet 1995; 346: 1179-84.
  11. Marui A, Kimura T, Nishiwaki N, Mitsudo K, Komiya T, Hanyu M, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). The American journal of cardiology 2014; 114: 555-61.
  12. Becher T, Baumann S, Eder F, Perschka S, Loßnitzer D, Fastner C, et al. Comparison of peri and post-procedural complications in patients undergoing revascularisation of coronary artery multivessel disease by coronary artery bypass grafting or protected percutaneous coronary intervention with the Impella 2.5 device. European Heart Journal: Acute Cardiovascular Care 2019; 8: 360-8.
  13. Gunn J, Kuttila K, Kiviniemi T, Ylitalo A, Biancari F, Juvonen T, et al. Outcome after coronary artery bypass surgery and percutaneous coronary intervention in patients with atrial fibrillation and oral anticoagulation. Annals of medicine 2014; 46: 330-4.
  14. Rodriguez A, Boullon F, Perez-Baliño N, Paviotti C, Liprandi MIS, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. Journal of the American College of Cardiology 1993; 22: 1060-7.
  15. Hällberg V, Palomäki A, Lahtela J, Voutilainen S, Tarkka M, Kataja M. Associations of metabolic syndrome and diabetes mellitus with 16-year survival after CABG. Cardiovascular diabetology 2014; 13: 25.
  16. Abdallah MS, Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, et al. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. Jama 2013; 310: 1581-90.
  17. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary Artery Bypass Grafting vs Percutaneous Coronary Intervention and Long-term Mortality and Morbidity in Multivessel Disease: Meta-analysis of Randomized Clinical Trials of the Arterial Grafting and Stenting Era. JAMA Internal Medicine 2014; 174. doi: 10.1001/jamainternmed.2013.12844
  18. Hannan EL, Racz MJ, McCallister BD, Ryan TJ, Arani DT, Isom OW, et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology 1999; 33: 63-72.
  19. Kapur A, Bartolini D, Finlay MC, Qureshi AC, Flather M, Strange JW, et al. The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease. Journal of Cardiovascular Medicine 2010; 11: 26-33.
  20. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. Journal of the American College of Cardiology 2010; 55: 432-40.
  21. Mohr FW, Morice M-C, Kappetein AP, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. The lancet 2013; 381: 629-38.
  22. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Journal of the American College of Cardiology 2015; 65: 2496-507.
  23. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus eluting stents versus coronary artery bypass graft surgery for patients with diabetes mellitus and multivessel disease. Circulation: Cardiovascular Interventions 2015; 8: e002626.
  24. Shiomi H, Morimoto T, Hayano M, Furukawa Y, Nakagawa Y, Tazaki J, et al. Comparison of long-term outcome after percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). The American journal of cardiology 2012; 110: 924-32.
  25. Fink N, Nikolsky E, Assali A, Shapira O, Kassif Y, Barac YD, et al. Revascularization strategies and survival in patients with multivessel coronary artery disease. The Annals of thoracic surgery 2019; 107: 106-11.
Iranian Heart Journal
Volume 23, Issue 1
Winter 2022
Pages 25-33